The company posted better-than-expected second-quarter sales on Tuesday on strong demand for its two top-selling products, cancer immunotherapy Keytruda and human papillomavirus (HPV) vaccine Gardasil.
According to the lead attorneys’ websites, the plaintiffs claim the Gardasil vaccine’s manufacturer “did not provide adequate warning of possible side effects associated with the product and that Merck fraudulently concealed evidence about the health risks of the vaccine while at the same time misrepresenting that Gardasil could prevent cervical cancer.”
Drugmaker Merck & Co. Inc. on Thursday posted better-than-expected results for the first quarter on the strength of its blockbuster cancer immunotherapy Keytruda and human papillomavirus (HPV) vaccine Gardasil.
Merck & Co. on Thursday forecast 2023 earnings below Wall Street estimates along with an expected steep decline in sales of its COVID-19 antiviral treatment, and its shares fell around 2%.
Merck & Co. on Thursday reported better-than-expected third-quarter sales and profit on a jump in demand for blockbuster cancer immunotherapy Keytruda and human papillomavirus vaccine Gardasil.
Merck’s exceptional revenue growth in 2021 and the first half of 2022 came thanks to three big brands, one of which is not even approved by the FDA yet.